R. Alemany
Committee Chairman
editor and reviewer
VCNBiosciences
Spain
Biography
Dr. Alemany is an internationally recognized expert in oncolytic adenoviruses for cancer treatment. He has more than 80 original publications and numerous patents in the fields of Gene Therapy and Virotherapy. He acts as editor and reviewer for the main international journals in these fields. From 1994 to 2001, Dr. Alemany held various research positions in USA at the MD Anderson Cancer Center (Houston, TX), Baxter Healthcare (Round Lake, IL), and the University of Alabama at Birmingham. He established the Virotherapy Group at the Translational Research Laboratory of the Institut Català d'Oncologia in 2001 and co-founded VCN together with Drs. Cascalló and Capellà in 2009 as a spin-off from this group. Dr. Alemany has been on the Executive Board of the Spanish Society of Gene and Cell Therapy and consultant for several companies based on adenoviruses. Dr. Alemany is an internationally recognized expert in oncolytic adenoviruses for cancer treatment. He has more than 80 original publications and numerous patents in the fields of Gene Therapy and Virotherapy. He acts as editor and reviewer for the main international journals in these fields. From 1994 to 2001, Dr. Alemany held various research positions in USA at the MD Anderson Cancer Center (Houston, TX), Baxter Healthcare (Round Lake, IL), and the University of Alabama at Birmingham. He established the Virotherapy Group at the Translational Research Laboratory of the Institut Català d'Oncologia in 2001 and co-founded VCN together with Drs. Cascalló and Capellà in 2009 as a spin-off from this group. Dr. Alemany has been on the Executive Board of the Spanish Society of Gene and Cell Therapy and consultant for several companies based on adenoviruses.
Research Interest
oncolytic adenoviruses for cancer treatment.
